PATENT CLAIM ANALYSIS

Application Number: 15928123
Application Type: Utility
Filing Date: 2018-03
Publication Date: 2018-07
Patent Classification: ["424", "085600"]

Abstract:
The present invention relates to the use of multiple doses of Cladribine combined with beta interferon for the treatment of multiple sclerosis in patients who are refractory to at least one conventional therapy.

Claim (Index 11):
The method of  claim 8 , wherein the combined duration of the induction period (i) and the Cladribine-free period (ii) is about 1 year, the combined duration of the maintenance period (iii) and the Cladribine-free period (iv) is about 1 year, the total dose of Cladribine administered during the first year of treatment is about 3.5 mg/kg and the total dose of Cladribine administered during the second year of treatment is about 1.7 mg/kg.

Metadata:
- Claim Count in Document: 5.0
- Percentile: 90.0
- Lexical Diversity: 1.17241
- Patent Class: 424.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: True
- Related Applications: ['12301083', '11722018', '12766173', '09904263', '15032919']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7590845155491402
- 35 USC 102 Novelty (BERT): 0.5691133577074577
- Combined Prediction Score: 0.7400873997649721
- Mean Citation Score: 317.2390000000001
- Max Citation Score: 446.3266
- Similarity Product: 419.00480437119

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test